GILD: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/ac41b0f3-cc9a-4379-8d65-65f11afb5b18/","filing_uuid":"ac41b0f3-cc9a-4379-8d65-65f11afb5b18","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/ac41b0f3-cc9a-4379-8d65-65f11afb5b18/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mike McKay, Principal","dt_posted":"2026-07-16T14:05:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1050 17th Street NW","registrant_address_2":"Suite 550","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400703105,"url":"https://lda.gov/api/v1/registrants/400703105/","house_registrant_id":null,"name":"EMPIRE CONSULTING GROUP","description":"Government Relations","address_1":"1050 17th Street NW","address_2":"Suite 550","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MIKE MCKAY","contact_telephone":"+1 202-787-5740","dt_updated":"2026-07-27T21:03:40.855794-04:00"},"client":{"id":194397,"url":"https://lda.gov/api/v1/clients/194397/","client_id":152,"name":"GILEAD SCIENCES INC.","general_description":"Biopharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-07-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to triple negative breast cancer treatment. Issues related to health access.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":53388,"prefix":null,"prefix_display":null,"first_name":"MIKE","nickname":null,"middle_name":null,"last_name":"MCKAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107217,"prefix":null,"prefix_display":null,"first_name":"E.","nickname":null,"middle_name":"BRANDON","last_name":"GARRETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}